CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Servier

Erik Lemay, Global Head of External Manufacturing

Overcoming The Medical Industry's Supply Chain Challenges

Erik Lemay

Erik Lemay

Since the pandemic began, industries across the globe have been impacted by significant and widespread supply chain issues – a reality that's perhaps no more apparent than in healthcare. Just consider that 99 percent of U.S. hospitals and health systems have reported experiencing challenges in supply procurement, including notable shortages of key items. The pandemic has exposed longstanding gaps in our medical supply chain, leaving business leaders with hard-learned lessons about the future of the pharmaceutical industry, namely: In the face of external challenges, we still have work to do.


Below, are insights that can help pharmaceutical companies circumnavigate supply-chain bottlenecks plaguing our industry and are critical to ensuring people get the necessary treatments they need.


Focus on Digital


Today, supply chains can greatly benefit from digital integrations, harnessing the latest in artificial intelligence (AI), machine learning and data analytics to anticipate problems and ultimately deliver medicines faster and more safely to patients. It’s for this reason and more that approximately 88% of healthcare executives identify AI as a ‘critical’ technology for supply chains in the next three years. By leveraging innovative digital advancements, organizations can gain real-time insights and make data-informed decisions to mitigate supply-chain disruptions.


“Companies looking to mitigate third-party disruptions would be wise to integrate visibility and accountability at each step of the product journey.”


Lead with Oversight


For any pharma company, having direct oversight across every juncture of your supply chain is often easier said than done. In fact, third-party manufacturing, product handling, and transportation are all considered to be “tricks of the trade.” Unfortunately, when one step has a delay, it can lead to negative impacts across the entire process, especially for medications with shorter shelf-lives.


 


Accordingly, companies looking to mitigate third-party disruptions would be wise to integrate visibility and accountability at each step of the product journey. Forward looking analysis is a critical component of this, as it can ensure that you have appropriate safety stocks of all materials across your supply chain. Additionally, it is best to incorporate dual sourcing throughout your supply chain, if financially feasible.


Whether it’s arming your teams with new, real-time data monitoring protocols or collaborating with the right partners, companies should take steps to be more intimately involved in their operating practices– instilling oversight along the way.


Don’t Forget R&D


When we think about the medical supply chain, many of us are quick to focus on commercialization. While this is certainly a priority it overlooks a critical aspect of drug manufacturing: You can’t deliver what you don’t develop. It’s important to remember supply chains aren’t just needed for product manufacturing, they’re also needed to progress therapeutics through clinical trials. By making a concerted effort to include R&D in supply chain conversations whenever a disruption occurs, business leaders can get an adequate understanding of potential pipeline impacts and find solutions that overcome them. 


If the pandemic has shown us anything, it’s how quickly the world can change, and how important it is that pharmaceutical companies keep up with the pace. With every delay, comes a patient who doesn’t receive their medicine. With every disruption, comes a clinical trial that can’t launch. As leaders, we always have to think one-step ahead in order to keep supply chains running in the face of the unexpected. By following these tips, we can do so faster, safer and more reliably, ensuring our supply chains reach those in need, when they need it most.


Check Out This : Semiconductor Manufacturing Solutions Companies


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://cdmo.lifesciencesreview.com/leadership-perspective/overcoming-the-medical-industry-s-supply-chain-challenges-nwid-891.html